TY - JOUR
TI - Estimating the money flow in the economy attributed to rotavirus disease and vaccination in the Netherlands using a Social Accounting Matrix (SAM) framework
AU - Kotsopoulos, N.
AU - Haitsma, G.
AU - Connolly, M.P.
AU - Standaert, B.
JO - Expert Review of Pharmacoeconomics and Outcomes Research
PY - 2020
VL - 20
TODO - 6
SP - 603-612
PB - Taylor and Francis Ltd.
SN - 1473-7167, 1744-8379
TODO - 10.1080/14737167.2020.1693269
TODO - Rotavirus vaccine;  Rotavirus vaccine, Article;  cost effectiveness analysis;  economic aspect;  epidemiological data;  health care cost;  health care policy;  health insurance;  health program;  health service;  household income;  human;  Netherlands;  population size;  Rotavirus infection;  sensitivity analysis;  social accounting matrix;  vaccination;  economics;  gastroenteritis;  infant;  Netherlands;  preschool child;  preventive health service;  Rotavirus infection;  theoretical model;  vaccination;  virology, Child, Preschool;  Gastroenteritis;  Humans;  Immunization Programs;  Infant;  Models, Theoretical;  Netherlands;  Rotavirus Infections;  Rotavirus Vaccines;  Vaccination
TODO - Background: The economics of rotavirus gastroenteritis in infants <5 years old is well-known within healthcare. The financial consequences for families, employers and authorities are not so well explored. The present study evaluates how vaccine prevention changes money flows among those involved in the management of disease, and its consequences. Methods: A Social Accounting Matrix (SAM) framework has been developed reflecting the distribution of income and spending at equilibrium affected by rotavirus disease among all those concerned for 1 year. The data came from official sources and published literature. A comparison of the financial equilibrium between with and without a national rotavirus immunization program has been conducted, along with sensitivity analysis for the results. Results: The total financial cost difference at equilibrium between presence and absence of rotavirus vaccination was +€26.758 million over one year as a net economic surplus. The payment of vaccination (€19.194 million) by the government was offset by the increase in tax revenue (€14.561 million) and by the lower spending in treatment care (€7.998 million). Conclusion: Studying the financial flows between different transacting agents can demonstrate the financial burden of a disease and the benefits of its prevention on agents’ income and spending. © 2019 GlaxoSmithKline Biologicals S.A. Published by Informa UK Limited, trading as Taylor & Francis Group.
ER -